Catalent Inc (CTLT)
56.23
-0.18
(-0.32%)
USD |
NYSE |
Jun 28, 16:00
56.17
-0.06
(-0.11%)
Pre-Market: 20:00
Catalent SG&A Expense (Quarterly): 214.00M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 214.00M |
December 31, 2023 | 250.00M |
September 30, 2023 | 205.00M |
June 30, 2023 | 217.00M |
March 31, 2023 | 190.00M |
December 31, 2022 | 226.00M |
September 30, 2022 | 196.00M |
June 30, 2022 | 226.00M |
March 31, 2022 | 207.00M |
December 31, 2021 | 228.00M |
September 30, 2021 | 183.00M |
June 30, 2021 | 184.00M |
March 31, 2021 | 173.00M |
December 31, 2020 | 165.00M |
September 30, 2020 | 165.00M |
June 30, 2020 | 157.10M |
March 31, 2020 | 136.10M |
December 31, 2019 | 141.00M |
September 30, 2019 | 142.80M |
June 30, 2019 | 143.40M |
March 31, 2019 | 129.90M |
December 31, 2018 | 123.20M |
September 30, 2018 | 115.50M |
June 30, 2018 | 124.90M |
Date | Value |
---|---|
March 31, 2018 | 117.60M |
December 31, 2017 | 114.80M |
September 30, 2017 | 107.50M |
June 30, 2017 | 107.30M |
March 31, 2017 | 100.90M |
December 31, 2016 | 96.20M |
September 30, 2016 | 98.20M |
June 30, 2016 | 89.50M |
March 31, 2016 | 93.40M |
December 31, 2015 | 93.00M |
September 30, 2015 | 82.30M |
June 30, 2015 | 86.90M |
March 31, 2015 | 80.90M |
December 31, 2014 | 88.10M |
September 30, 2014 | 81.40M |
June 30, 2014 | 78.60M |
March 31, 2014 | 87.60M |
December 31, 2013 | 87.50M |
September 30, 2013 | 81.10M |
June 30, 2013 | 88.90M |
March 31, 2013 | 83.70M |
December 31, 2012 | 86.20M |
September 30, 2012 | 81.80M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
136.10M
Minimum
Mar 2020
250.00M
Maximum
Dec 2023
187.47M
Average
187.00M
Median
SG&A Expense (Quarterly) Benchmarks
Eli Lilly and Co | 1.836B |
Align Technology Inc | 451.82M |
Amgen Inc | 1.808B |
Gilead Sciences Inc | 1.375B |
Johnson & Johnson | 5.057B |